EGFR and central nervous system cancer: The significant interactions identified running scTHI in paracrine mode, and most common among all patients with glioma, were VCAN-TLR2 (72% of patients, P = 4.40 · 10−67) and HBEGF-EGFR (51% of patients, P = 6.97 · 10−44) (Fig. 3 and Fig. S5).